This case provides valuable real-world evidence supporting further investigation of pyrotinib as a personalized treatment strategy in HER2-driven NSCLC, particularly in patients harboring the ERBB2 exon 20 Y772_A775dup mutation. Here, ERBB2 is linked to non-small cell lung carcinoma.